Lourenço Juliana D, Neves Luana P, Olivo Clarice R, Duran Adriana, Almeida Francine M, Arantes Petra M M, Prado Carla M, Leick Edna Aparecida, Tanaka Aparecida S, Martins Mílton A, Sasaki Sergio D, Lopes Fernanda D T Q S
Department of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
Centro de Ciências Naturais e Humanas, UFABC, Santo André, Sao Paulo, Brazil.
PLoS One. 2014 Jun 2;9(6):e98216. doi: 10.1371/journal.pone.0098216. eCollection 2014.
To determine whether a serine protease inhibitor treatment can prevent or minimize emphysema in mice.
C57BL/6 mice were subjected to porcine pancreatic elastase (PPE) nasal instillation to induce emphysema and were treated with a serine protease inhibitor (rBmTI-A) before (Protocol 1) and after (Protocol 2) emphysema development. In both protocols, we evaluated lung function to evaluate the airway resistance (Raw), tissue damping (Gtis) and tissue elastance (Htis). The inflammatory profile was analyzed in the bronchoalveolar lavage (BALF) and through the use of morphometry; we measured the mean linear intercept (Lm) (to verify alveolar enlargement), the volume proportion of collagen and elastic fibers, and the numbers of macrophages and metalloprotease 12 (MMP-12) positive cells in the parenchyma. We showed that at both time points, even after the emphysema was established, the rBmTI-A treatment was sufficient to reverse the loss of elastic recoil measured by Htis, the alveolar enlargement and the increase in the total number of cells in the BALF, with a primary decrease in the number of macrophages. Although, the treatment did not control the increase in macrophages in the lung parenchyma, it was sufficient to decrease the number of positive cells for MMP-12 and reduce the volume of collagen fibers, which was increased in PPE groups. These findings attest to the importance of MMP-12 in PPE-induced emphysema and suggest that this metalloprotease could be an effective therapeutic target.
确定丝氨酸蛋白酶抑制剂治疗是否能预防或减轻小鼠肺气肿。
对C57BL/6小鼠进行猪胰弹性蛋白酶(PPE)滴鼻诱导肺气肿,并在肺气肿发生前(方案1)和发生后(方案2)用丝氨酸蛋白酶抑制剂(rBmTI-A)进行治疗。在两个方案中,我们评估肺功能以评估气道阻力(Raw)、组织阻尼(Gtis)和组织弹性(Htis)。在支气管肺泡灌洗(BALF)中并通过形态计量学分析炎症特征;我们测量平均线性截距(Lm)(以验证肺泡扩大)、胶原蛋白和弹性纤维的体积比例,以及实质内巨噬细胞和金属蛋白酶12(MMP-12)阳性细胞的数量。我们发现,在两个时间点,即使在肺气肿形成后,rBmTI-A治疗也足以逆转通过Htis测量的弹性回缩丧失、肺泡扩大以及BALF中细胞总数的增加,其中巨噬细胞数量主要减少。虽然该治疗未能控制肺实质中巨噬细胞的增加,但足以减少MMP-12阳性细胞的数量并减少胶原蛋白纤维的体积,而在PPE组中胶原蛋白纤维体积增加。这些发现证明了MMP-12在PPE诱导的肺气肿中的重要性,并表明这种金属蛋白酶可能是一个有效的治疗靶点。